> ## Content Index
> Fetch the complete content index at: https://www.melaninblissmedia.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# The Pain They Didn't Believe
- URL: https://www.melaninblissmedia.com/the-pain-they-didnt-believe/
- Published: 2026-09-14T17:01:54.000Z
- Updated: 2026-09-14T17:01:54.000Z
- Author: Amber McClendon

*Sickle cell disease affects about 100,000 Americans — nearly nine in ten of them Black. For a century, medicine underfunded it, and disbelieved the people living it. September is when we say their names.*

---

There is a particular cruelty in a disease whose defining symptom is agony, treated by a system trained to doubt the person in pain. That is the story of sickle cell disease in America and it is, almost entirely, a Black story.

About 100,000 people in the United States live with sickle cell disease, and more than 90 percent of them are Black or African American. It is an inherited blood disorder that twists red blood cells into rigid crescents, blocking vessels and triggering “pain crises” that patients describe as bones being crushed from the inside. It can bring strokes, organ damage, and early death. And for generations, the people enduring it have walked into emergency rooms in genuine crisis and been met not with morphine but with suspicion.

The research bears out what patients have said for decades. Medical literature documents providers describing sickle cell patients as “drug-seeking” or “over-reporting” their pain and under-prescribing not just pain medication but even non-addictive, standard-of-care treatments like hydroxyurea. The pain was real. The disbelief was the policy.

***The pain was real. The disbelief was the policy.***

Follow the money and the picture sharpens. Researchers have found that a disease like cystic fibrosis which affects roughly 30,000 people, most of them white has historically drawn more than three times as many NIH research grants as sickle cell, which affects more than three times as many people. Fewer patients, whiter patients, more money. That is not a coincidence. That is a value judgment, made in a budget.

There is, finally, something like hope. In late 2023, the FDA approved the first gene therapies for sickle cell including the first CRISPR-based treatment ever cleared in the United States offering the possibility of a functional cure. It is a genuine scientific triumph. It is also priced in the millions of dollars, and uptake among the Black patients it was built for has been slow, tangled in cost, access, and the same fragmented care that has always defined this disease. A cure that the people who need it cannot reach is a promise, not a solution.

So this Sickle Cell Awareness Month, the work is not just to raise a ribbon. It is to name the pattern: a disease was underfunded because of who it hurt, its patients were disbelieved because of who they were, and now a cure exists that too many of them still can't touch. Believing Black pain in the ER, in the lab, in the federal budget was always the treatment we skipped.

We say their names this month because for a hundred years, medicine acted like it couldn't hear them.

*Sources: Journal of Racial and Ethnic Health Disparities (2025); The American Journal of Managed Care (2024); “The Bias of Medicine in Sickle Cell Disease,” Journal of General Internal Medicine (2023); U.S. FDA approvals of Casgevy and Lyfgenia (December 2023); National Sickle Cell Awareness Month proclamation (2024). Figures reflect the cited sources. Informational, not medical advice.*